Human gene therapy: present and future.
The hematopoietic system and the liver are two primary target organs for attempting somatic gene therapy of hereditary deficiencies. Several leading laboratories have recently been able to demonstrate that bone marrow cells from rodents and non-human primates can be successfully transduced with foreign genes, resulting in the functional expression of these genes in culture. The genetically reconstituted cells can subsequently be transplanted into X-irradiated recipients, and expression of the transduced genes is observed in the recipients for more than 6 months. Subsequently, gene transfer into peripheral T-lymphocytes in humans has been attempted, and the clinical trials are currently in progress. The liver is the other major organ under intensive investigation. Primary hepatocytes can be isolated from rodents, rabbits, and dogs, and successfully transduced with recombinant retroviruses. After autologous transplantation, long term survival of the engrafted cells in vivo has been observed. More recently, it has been shown that human hepatocytes can also be efficiently transduced with recombinant retroviruses. These experimental results have laid the foundation for somatic gene therapy of hereditary deficiencies in humans in the future.
Kay
M A
MA
Department of Cell Biology, Baylor College of Medicine, Houston TX 77030.
Ponder
K P
KP
Woo
S L
SL
D000818:Animals; D004285:Dogs; D005544:Forecasting; D015316:Genetic Therapy / Q000639:trends*; D006801:Humans; D016031:Liver Transplantation / Q000379:methods; D008954:Models, Biological; D010641:Phenotype; D011995:Recombination, Genetic; D012191:Retroviridae Proteins / Q000235:genetics; D014162:Transfection; D000515:alpha 1-Antitrypsin / Q000235:genetics; D019896:alpha 1-Antitrypsin Deficiency
D012191:Retroviridae Proteins; D000515:alpha 1-Antitrypsin